Search Results

Timing of Dose Relative to Sexual Intercourse Attempt in Previous Sildenafil Citrate Users Treated with Tadalafil: A Geographical Comparison from a Single Arm, Open-Label Study

Authors: Rubio-Aurioles, Eusebio; Glina, Sidney; Abdo, Carmita H.N.; Hernandez-Serrano, Ruben; Rampazzo, Claudia; Sotomayor, Mariano; West, Teena M.; Gallagher, Gabrielle L.; Lenero, Enrique

Source: The Journal of Sexual Medicine, Volume 6, Number 10, October 2009 , pp. 2836-2850(15)

Publisher: Blackwell Publishing

Phosphodiesterase Type 5 Inhibitors for the Management of Erectile Dysfunction: Preference and Adherence to Treatment

Authors: Al-Shaiji, T. F.; Brock, G. B.

Source: Current Pharmaceutical Design, Volume 15, Number 30, October 2009 , pp. 3486-3495(10)

Publisher: Bentham Science Publishers

The burden and extent of comorbid conditions in patients with erectile dysfunction

Author: Hackett, G.

Source: International Journal of Clinical Practice, Volume 63, Number 8, August 2009 , pp. 1205-1213(9)

Publisher: Blackwell Publishing

Toward a new `EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction

Authors: Sadovsky, R.; Brock, G. B.; Gutkin, S. W.; Sorsaburu, S.

Source: International Journal of Clinical Practice, Volume 63, Number 8, August 2009 , pp. 1214-1230(17)

Publisher: Blackwell Publishing

Five-year experience with tadalafil in the UK: an effective treatment for erectile dysfunction

Author: Dinsmore, W.

Source: International Journal of Clinical Practice, Volume 63, Number 8, August 2009 , pp. 1231-1236(6)

Publisher: Blackwell Publishing

The Role of PDE5 Inhibitors in Heme Oxygenase-cGMP Relationship in Rat Cavernous Tissues

Authors: Aziz, M. Talaat Abdel; Mostafa, Taymour; Atta, Hazem; Rashed, Laila; Marzouk, Samar A.; Obaia, Eman M.; Sabry, Dina; Hassouna, Amira A.; El-Shehaby, Amal M.; Aziz, Ahmed T. Abdel

Source: The Journal of Sexual Medicine, Volume 5, Number 7, July 2008 , pp. 1636-1645(10)

Publisher: Blackwell Publishing

Effects of phosphodiesterase 5 inhibitors on sperm parameters and fertilizing capacity

Authors: Dimitriadis, F.; Giannakis, D.; Pardalidis, N.; Zikopoulos, K.; Paraskevaidis, E.; Giotitsas, N.; Kalaboki, V.; Tsounapi, P.; Baltogiannis, D.; Georgiou, I.; Saito, M.; Watanabe, T.; Miyagawa, I.; Sofikitis, N.

Source: Asian Journal of Andrology, Volume 10, Number 1, January 2008 , pp. 115-133(19)

Publisher: Blackwell Publishing

Treatment preferences in men with erectile dysfunction: an open label study in Korean men switching from sildenafil citrate to tadalafil

Authors: Ahn, Tai Young; Lee, Sung Won; Kim, Sae-Woong; Yang, Dae Yul; Park, Nam Cheol; Min, Kweon-Sik; Park, Kwangsung; Paick, Jae-Seung; Dyachkova, Yulia; Dwight, Trisha; Lee, Myung-Sea Luke

Source: Asian Journal of Andrology, Volume 9, Number 6, November 2007 , pp. 760-770(11)

Publisher: Blackwell Publishing

Oral phosphodiesterase-5 inhibitors: effect of heme oxygenase inhibition on cGMP signalling in rat cavernous tissue

Authors: Abdel Aziz, M. T.; Mostafa, T.; Atta, H.; Rashed, L.; Marzouk, S. A.; Obaia, E. M.; Sabry, D.; Hassouna, A. A.; El-Shehaby, A. M.; Abdel Aziz, A.T.

Source: Andrologia, Volume 39, Number 2, April 2007 , pp. 66-70(5)

Publisher: Blackwell Publishing

Feasibility of the Use of Phosphodiesterase Type 5 Inhibitors in a Pharmacologic Prevention Program for Recurrent Priapism

Authors: Burnett, Arthur L.; Bivalacqua, Trinity J.; Champion, Hunter C.; Musicki, Biljana

Source: The Journal of Sexual Medicine, Volume 3, Number 6, November 2006 , pp. 1077-1084(8)

Publisher: Blackwell Publishing

Densitometric Determination of Tadalafil Citrate in Tablets: Validation of the Method

Authors: Berniati Tampubolon, Hosiana; Sumarlik, Endang; Dwi Saputra, Setiawan; Cholifah, Siti; Farina Kartinasari, Wiwin; Indrayanto, Gunawan

Source: Journal of Liquid Chromatography & Related Technologies, Volume 29, Number 18, 2006 , pp. 2753-2765(13)

Publisher: Taylor and Francis Ltd

Comparison of phosphodiesterase type 5 (PDE5) inhibitors

Author: WRIGHT, P. J.

Source: International Journal of Clinical Practice, Volume 60, Number 8, August 2006 , pp. 967-975(9)

Publisher: Blackwell Publishing

Tadalafil for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia

Authors: Gonzalez, Ricardo R; Kaplan, Steven A

Source: Expert Opinion on Drug Metabolism and Toxicology, Volume 2, Number 4, August 2006 , pp. 609-617(9)

Publisher: Informa Healthcare

`Sex for life'? Men's counter-stories on `erectile dysfunction', male sexuality and ageing

Authors: Potts, Annie; Grace, Victoria M.; Vares, Tiina; Gavey, Nicola

Source: Sociology of Health & Illness, Volume 28, Number 3, April 2006 , pp. 306-329(24)

Publisher: Blackwell Publishing

Timing of Dose Relative to Sexual Intercourse Attempt in Previous Sildenafil Citrate Users Treated with Tadalafil

Authors: Glina, Sidney; Sotomayor, Mariano; Gatchalian, Eduardo; Yaman, Onder; Dyachkova, Yulia; Markey, Caroline; Kopernicky, Vladimir

Source: The Journal of Sexual Medicine, Volume 3, Number 2, March 2006 , pp. 309-319(11)

Publisher: Blackwell Publishing

Medication Utilization Behavior in Patients Receiving Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction

Authors: Mulhall, John P.; McLaughlin, Trent P.; Harnett, James P.; Scott, Brian; Burhani, Soraya; Russell, David

Source: The Journal of Sexual Medicine, Volume 2, Number 6, November 2005 , pp. 848-855(8)

Publisher: Blackwell Publishing

Sensitivity of the Psychological and Interpersonal Relationship Scales to Oral Therapies for Erectile Dysfunction

Authors: Rosen, Raymond; Broderick, Gregory; Shabsigh, Ridwan; Swindle, Ralph; Lockhart, Daniel; Cameron, Ann

Source: The Journal of Sexual Medicine, Volume 2, Number 4, July 2005 , pp. 461-468(8)

Publisher: Blackwell Publishing

Emerging oral drugs for erectile dysfunction

Authors: Briganti A.; Salonia A.; Gallina A.; Suardi N.; Rigatti P.; Montorsi F.

Source: Expert Opinion on Emerging Drugs, Volume 9, Number 1, 1 May 2004 , pp. 179-189(11)

Publisher: Informa Healthcare

A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction

Authors: Govier F.; Potempa A.-J.; Kaufman J.; Denne J.; Kovalenko P.; Ahuja S.

Source: Clinical Therapeutics, Volume 25, Number 11, November 2003 , pp. 2709-2723(15)

Publisher: Elsevier

Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: Results of a European multicenter, open-label study of patient preference

Authors: Stroberg P.; Murphy A.; Costigan T.

Source: Clinical Therapeutics, Volume 25, Number 11, November 2003 , pp. 2724-2737(14)

Publisher: Elsevier